Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Xenon Pharmaceuticals Inc.

The latest announcement is out from Xenon ( ($XENE) ). Xenon Pharmaceuticals has released new data from its ongoing X-TOLE open-label extension stu...

Xenon Pharmaceuticals Unveils Promising Long-Term Epilepsy Treatment Data

Xenon ( ($XENE) ) just unveiled an announcement. Xenon Pharmaceuticals announced the issuance of equity inducement grants to five new non-officer e...

Xenon Pharmaceuticals Issues Equity Inducement Grants to New Employees

In a report released today, Benjamin Burnett from Wells Fargo maintained a Buy rating on Xenon, with a price target of $44.00. Burnett covers the H...

Wells Fargo Sticks to Its Buy Rating for Xenon (XENE)

H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Xenon today and set a price target of $53.00. According to TipRanks, Tsao is a 5-st...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	XENE	$44.06	+0.92%	821.05K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	XENE	$44.06	+0.9%	821.05K
3
4
5
6

XENE

XENE

No Data Available

Get Xenon Pharmaceuticals Inc. Data in Excel

Get Xenon Pharmaceuticals Inc. Data in Excel